B

BioLineRx Ltd
D

BLRX

0.27790
USD
0.00
(0.40%)
مغلق
حجم التداول
12,599
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
23,374,754
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADVM
    -0.40000
    (-5.51%)
    6.86000 USD
    A
    ARDX
    0.25000
    (5.30%)
    4.96500 USD
    B
    BPMC
    -6.990
    (-7.31%)
    88.690 USD
    I
    ICPT
    0
    (0%)
    0.000000 USD
    I
    INVA
    -0.355
    (-1.84%)
    18.910 USD
    R
    RDHL
    0.24000
    (3.40%)
    7.29000 USD
    T
    TNXP
    -0.00910
    (-6.53%)
    0.13030 USD
    المزيد
الأخبار

العنوان: BioLineRx Ltd

القطاع: Healthcare
الصناعة: Biotechnology
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.